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Someevidencesuggeststheneuroprotectionofestrogenprovidedbytheantioxidantactivityofthiscompound.Themainobjective
of this study was to determine the level of estradiol and its correlation with the activity of antioxidant enzymes, total antioxidant
status and ferritin from ischemic stroke subjects. The study population consisted of 30 patients with acute ischemic stroke and 30
controls. There was no signiﬁcant diﬀerence between estradiol in stroke and control group. The activity of superoxide dismutase
and level of ferritin was higher in stroke compared with control group (P<. 05, P<. 001, resp.). There was no signiﬁcant
correlation between estradiol and glutathione peroxidase, glutathione reductase, catalase, total antioxidant status, and ferritin in
strokeandcontrolgroups.Weobservedinversecorrelationbetweenestradiolwithsuperoxidedismutaseinmalesofstrokepatients
(r =− 0.54, P = .029). Our results supported that endogenous estradiol of elderly men and women of stroke or control group has
no antioxidant activity.
Copyright © 2009 Nasrin Sheikh et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Stroke is the third most common cause of death, particularly
in the elderly. Ischemic stroke accounts for about 75% of
all cases while hemorrhagic stroke is responsible for almost
15% of all strokes [1]. Data on the link between endogenous
estrogen and ischemic stroke in elderly men and women is
limited and controversial [2]. Before the menopause, women
are relatively protected from ischemic stroke compared with
men. This protection is most attributed to the action of
estrogen [3, 4] but recent evidence has raised the possibility
that sex-dependent diﬀerences in vascular oxidative stress
may play a role [5]. In postmenopausal women and elderly
men, the role of endogenous estrogen is not clear. Some
studies have found that hyperestrogenemia is related to an
elevated risk of coronary heart disease, although other stud-
ies have not [6]. Abbott et al. found elderly men with high
level of serum estradiol have twofold excess risk of stroke
compared with men whose estradiol levels were lower [6].
Relationship between endogenous estradiol and antioxidant
status of elderly men and women from stroke is less known.
Some evidences suggest the neuroprotective of estrogen or
estrogen derivatives provided by the antioxidant activity
of this compound [7], but some studies are observed the
antioxidant activity of estrogen, only with supraphysiologic
dose of estrogen [8].
Since oxidative stress is important mechanism involved
in ischemic stroke, the activity of antioxidant enzymes may
be an essential factor providing protection from neurological
damage[1,9,10].Ferrettietal.foundthehigherleveloflipid
hydroperoxides in plasma from stroke patients compared
with control group [11]. The question whether endogenous
estradiolcanaﬀecttheactivityofantioxidantenzymeorlevel
of ferritin in the ischemic stroke has not been systematically
addressed yet, although the activity of antioxidant enzyme
and level of ferritin from stroke patients have been reported2 Journal of Biomedicine and Biotechnology
[9, 10, 12, 13]. To the best of our knowledge, no information
is available about correlation between endogenous estradiol
and the activity of antioxidant enzymes from ischemic stroke
patients. The main objective of this study was to determine
the level of estradiol and its correlation with the activity
of antioxidant enzymes and ferritin from ischemic stroke
subjects.
2.MaterialsandMethods
Thirty patients older than 61 years with acute ischemic
stroke admitted within 12 hours from the onset of symp-
toms to the emergency room of the Farshchian University
Hospital, Hamadan, Iran, and were consecutively enrolled.
On admission, demographic characteristics, a detailed his-
tory, and clinical information for stroke risk factors were
recorded. Laboratory tests (blood cell count, biochemical
studies including lipid proﬁles and serum electrolytes, urine
analysis), chest radiography, and electrocardiography were
performed in all patients. All patients were investigated to
clarify etiologic factors for stroke. Computed tomography
(CT)ofthebrainwasperformedinallpatients.Subjectswith
hemorrhagicstroke,otherneurologicaldisease,patientswith
bodytemperaturehigherthan37.5◦C,inﬂammatoryprocess,
diabetes mellitus, liver disease, and renal impairment, or
taking iron or antioxidant vitamins or hormone replacement
therapy during the months preceding the enrollment, were
excluded from the study. The severity of the neurological
deﬁcit was determind by Canadian Neurological Scale [14].
Heparinized venous blood samples were taken and plasma
was separated and stored at –70◦C. Results from the patient
group were compared with those obtained from 30 healthy
subjects of comparable age and gender. None of the control
subjects was undergoing pharmacological treatments. All
subjects gave informed consent to participate in the study,
according to the criteria of the Ethical Committee of
Hamadan University of Medical Sciences.
2.1. Estradiol Assay. Plasma 17-β estradiol was measured by
a quantitative competitive immunoassay kit (DRG Instru-
ments, Germany).
2.2. Glutathione Peroxidase Assay. Whole blood glutathione
peroxidase was measured by a kit from Ransel (Randox
Laboratories, UK). Glutathione peroxidase catalyses the
oxidation of glutathione by cumene hydroperoxide. In the
presence of glutathione reductase and NADPH, the oxidised
glutathione is immediately converted to the reduced form
with a concomitant oxidation of NADPH to NADP+.T h e
decrease in absorbance at 340nm is measured. The GPX
activity is expressed as U/L.
2.3. Superoxide Dismutase Assay. Whole blood superox-
ide dismutase activity was measured by a Kit from
Ransod (Randox Laboratories, UK), employing xanthine
and xanthine oxidase to generate superoxide radicals
which react with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-
phenyltetrazolium chloride (INT) to form a red formazan
dye. One unit SOD was the amount that causes a 50%
inhibition in the rate of reduction of INT.
2.4. Total Antioxidant Status Assay. Plasma total antioxidant
status was measured by a Kit from Randox Company.
ABTS (2,2-Azino-di-[3-ethylbenzthiazoline sulphonate])
is incubated with a peroxidase (metmyoglobin) and H2O2
to produce the radical cation ABTS+. Antioxidants in the
plasma cause suppression of cation ABTS+ to a degree that
is proportional to their concentration.
2.5. Glutathione Reductase Assay. Glutathione reductase
activity of the erythrocytes was measured by a Kit from Ran-
dox Company. Glutathione reductase catalyzes the reduction
of glutathione in the presence of NADPH, which is oxidized
to NADP+. The decrease in absorbance at 340nm is mea-
sured.
2.6. Catalase Assay. Catalase activity of the erythrocytes
was measured according to Abei (15) by monitoring the
initial rate of disappearance of hydrogen peroxide (initial
concentration 10mM) at 240nm. The catalase activity is
expressed as k/g Hb.
2.7. Ferritin Assay. Ferritin levels of the plasma were mea-
sured by a kit (Pyesthaste Company, Iran) using immunoas-
say technique.
3.StatisticalAnalysis
Results are expressed as means ± SD. Kolmogorov-Smirnov
goodness of test was used for normality distribution of
estradiol, total antioxidant status, superoxide dismutase,
glutathione peroxidase, glutathione reductase, catalase, and
ferritin. For comparing estradiol, total antioxidant status,
superoxide dismutase, glutathione peroxidase, glutathione
reductase, catalase, and ferritin between stroke and control
groups, the Student’s t test was used. In addition, correlation
analyses were performed by means of the Pearson test. A
value of P<. 05 was considered signiﬁcant.
4. Results
The study population consisted of 60 subjects: 30 patients
with acute ischemic stroke admitted within 12 hours from
onset (15 men and 15 women, aged70.6±8.3a n d7 0 .4±10.8
years, resp.) and 30 controls (15 men and 15 women, aged
68.5 ± 8.4a n d6 6 .2 ± 7.6 years, resp.). The mean CNS score
in stroke group was 6.3 ±1.5.
4.1. Results of Total Subjects from Stroke and Control Group.
The mean values of the estradiol, glutathione peroxidase,
glutathione reductase, catalase, superoxide dismutase, total
antioxidant status, and ferritin in the stroke and control
groups are shown in Table 1. There was no signiﬁcant
diﬀerencebetweenestradiolinstrokeandcontrolgroup.The
activity of superoxide dismutase and level of ferritin was
higher in stroke compared with control group (P<. 05,
P<. 001, resp.). The activity of glutathione peroxidase was
lower in stroke compared with control group (P<. 05).Journal of Biomedicine and Biotechnology 3
Table 1: The mean ± SD values of the estradiol, ferritin and total antioxidant status, superoxide dismutase and glutathione peroxidase,
glutathione reductase and catalase of the stroke and control group.
Parameters Stroke (n = 30) Control (n = 30)
Estradiol (pg/mL)† 63.8 ±19.86 6 .5 ±9.6
Superoxide dismutase‡ (U/mL) 174.53 ±84.81∗ 123.94 ±85.09
Glutathione peroxidase‡ (U/L) 3993.40 ±2696.19∗ 5775.27 ±3348.77
Glutathione Reductase# (U/g Hb) 2.78 ±1.87 3.03 ±1.93
Catalase (k/g Hb)# 492.97 ±115.39 456.11 ±103.96
Total antioxidant status (mmol/L)† 1.05 ±0.25 1.12 ±0.33
Ferritin (ng/mL)† 101.92 ±57∗∗ 66.54 ±30.91
†In plsama, ‡in whole blood, #in erythrocyte.
∗P<. 05, ∗∗P<. 001.
Table 2: The mean ± SD values of the estradiol, ferritin and total antioxidant status, superoxide dismutase and glutathione peroxidase,
glutathione reductase and catalase of the males from stroke and control groups.
Parameter Stroke (n = 15) Control (n = 15)
Estradiol† (pg/mL) 70 ±19.66 4 .5 ±6.9
Superoxide dismutase‡ (U/mL) 176.8 ±89.6∗ 112.5 ±62.6
Glutathione peroxidase‡ (U/L) 4107.9 ±3132.8 5791 ±3913
Glutathione reductase# (U/g Hb) 2.51 ±1.98 3.7 ±1.92
Catalase# (k/g Hb) 504.8 ±122.7 406.7 ±123.4
Total antioxidant status† (mmol/L) 1.05 ±0.26 1.2 ±0.34
Ferritin† (ng/mL) 111.9 ±60.5∗ 73 ±35.3
†In plsama, ‡in whole blood, #in erythrocyte.
∗P<. 05.
4.2. Results of Males and Females from Stroke and Control
Group. The mean ± SD values of the estradiol, ferritin,
and total antioxidant status, superoxide dismutase and
glutathione peroxidase, glutathione reductase, and catalase
of the males and females from stroke and control groups are
shown in Tables 2 and 3.
Thecorrelationbetweenestradiolandglutathioneperox-
idase, glutathione reductase, catalase, total antioxidant status
and ferritin in males and females from stroke and control
groups was not signiﬁcant. There was inverse correlation
between estradiol with superoxide dismutase in males of
stroke patients (r =− 0.54, P = .029). In addition, we
found inverse correlation between estradiol with superoxide
dismutase in females of stroke patients, but this diﬀerence
was not signiﬁcant (r =− 0.48, P = .13).
5. Discussion
In the present study, we have determined levels of estradiol,
ferritin, total antioxidant status, and activity of antioxidant
enzyme in ischemic stroke patients. Because of diﬃculties
in determination of antioxidant enzymes in human cerebral
tissue, the measurements were exclusively carried out in
blood samples. Data on the relationship of endogenous
estradiol and cerebrovascular disease in elderly men and
women are limited [2]. In our study, there was no diﬀerence
between estradiol in stroke and control group. This ﬁnding
suggests that the level of endogenous estradiol cannot
prevent of occurrence of ischemic stroke. Our results are
consistent with Abbott et al. who reported high levels of
serum estradiol that cannot protect elderly men against
stroke [6].
In the present study, ischemic stroke was associated with
increased plasma activity of superoxide dismutase during
the 12 hours after stroke. Because, after cerebral ischemia
and particularly reperfusion, free-radical production is dra-
matically elevated [15], thus increased superoxide dismutase
activity in stroke group may be a compensatory response
to oxidative stress in stroke. The result is in agreement
with Kocaturk et al. who have reported increased levels of
superoxide dismutase in red blood cells after cerebrovascular
accident [16].
In the present study, we did not observe positive
correlation between estradiol and glutathione peroxidase,
glutathione reductase, catalase, total antioxidant status, or
ferritin in stroke or control group. In contrast, we found
the negative correlation between estradiol and superoxide
dismutase activity in males from stroke group. These data
suggest a possible eﬀect of estradiol reduction on increase
of supreoxide anion and induce oxidative stress in these
patients. We suggested that increased of superoxide anion
could induce increased superoxide dismutase activity in
males of stroke patients which may be a compensatory
response to oxidative stress in these patients. However,
we observed inverse correlation between estradiol and
superoxide dismutase activity in females of stroke group,
but the diﬀerence was not signiﬁcant. The result is in
agreement with Bertrand et al. who have reported increased4 Journal of Biomedicine and Biotechnology
Table 3: The mean ± SD values of the estradiol, ferritin and total antioxidant status, superoxide dismutase and glutathione peroxidase,
glutathione reductase and catalase of the females from stroke and control groups.
Parameter Stroke (n = 15) Control (n = 15)
Estradiol† (pg/mL) 55.4 ±17.66 9 ±12
Superoxide dismutase‡ (U/mL) 171.4 ±81.5 137 ±106.5
Glutathione peroxidase‡ (U/L) 3861.2 ±2206.9 5758 ±2759
Glutathione reductase# (U/g Hb) 3.15 ±1.72 2.2 ±1.65
Catalase# (k/g Hb) 476.9 ±106.8 451.1 ±82.3
Total antioxidant status† (mmol/L) 1.06 ±0.25 1.02 ±0.31
Ferritin† (ng/mL) 87.6 ±50.75 8 .4 ±23.6
† In plsama, ‡In whole blood, #In erythrocyte.
level of serum total antioxidant status in postmenopausal
women after estrogen replacement therapy [17]. In the
other hand, our data suggests that endogenous estradiol do
not have antioxidant activity in stroke and control group
with age greater than 61 years. Some reports attributed an
antioxidant activity to estradiol but the antioxidant activity
is observed only with supraphysiologic concentration of this
hormone [8, 18, 19]. In the current report, evidence suggests
that neuroprotective eﬀects of endogenous estradiol against
stroke are not related to antioxidant eﬀect of this compound.
Itisnotclearwhetherestrogentherapyhaspotentialeﬀecton
oxidative stress in stroke patients. It seems that more studies
are needed to make clear the role of estrogen therapy on
antioxidant status of ischemic stroke patients.
Inthisstudy,weobservedhigherlevelofferritininstroke
compared with control group. Recent clinical studies have
been proposed that high plasma levels of ferritin might be
associated with increased risk of ischemic stroke [12, 13].
Ferritin might induce oxidative stress via being a donor of
free iron that is a source of hydroxyl radicals.
There are some limitations in the present study. First,
small number of stroke and control individuals. Second,
in this study, we did not determine correlations between
estradiol and reactive oxygen species or some metabolite of
lipid and DNA peroxidation such as malondialdehyde and 8-
oxoguanine in ischemic stroke group. Thus, further studies
are needed to clarify the role of endogenous estradiol on
antioxidant status of ischemic stroke patients.
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